PROFILES - Connect with RTRN Researchers

Bernard Arulanandam
Title Professor
Faculty Rank
Degree Ph.D.
Institution University of Texas at San Antonio
Department Biology
Clusters Other
Address
1 UTSA Cir
City San Antonio
State TX
Postal Code 78249
Telephone (210) 458-5492
Fax
Email
QR Barcode

Narrative icon

  Dr. Arulanandam’s research involves elucidating host-microbial interactions and cellular and molecular mechanisms involved in the induction of immune responses against infectious diseases. Despite a better understanding of systemic immune mechanisms, there are still challenges facing the vaccine field particularly in the area of mucosal defenses. Mucosal surfaces form the major interface between the host and the environment, and constitute the first line of defense against pathogens. The mammalian mucosal immune system has evolved into an intricate network of tissues, lymphoid and mucus membrane-associated cells and effector mechanisms for host protection. The mucosal surface area in humans is estimated to be 300-400 square meters and represents a significant portal of entry for pathogens. Thus, there is an important need to understand the basic mechanisms of immune defenses at these specialized sites.
Immunopathogenesis of Chlamydia trachomatis
There currently is no licensed vaccine against Chlamydia trachomatis, the leading cause of sexually transmitted bacterial disease worldwide. Untreated chlamydial infections induce immunopathology in the uterus and fallopian tubes, causing pelvic inflammatory disease (PID) and complications such as ectopic pregnancy and infertility. Persistence is thought to be a major cause of chlamydia-induced diseases in humans and may be due to chlamydial ability to evade host immune responses. Dr. Arulanandam’s lab is currently investigating various aspects of Chlamydia-induced pathogenesis utilizing genital and lung bacterial challenge models. The pathology produced by both genital (e.g., PID) and pulmonary infection of newborns (asthma-like consequences such as airway hyper-reactivity) result as a consequence of immunological sequeale to the primary or repeated infections with this pathogen. Overall, these studies provide valuable immunoregulatory insight into the design of viable vaccines against sexually transmitted disease resulting in infertility in adults and serious respiratory consequences in children born to infected mothers.
Respiratory Defenses against Pulmonary Tularemia
Francisella tularensis is an intracellular Gram-negative bacterium that is the causative agent of tularemia. Inhalation of F. tularensis results in severe disease and a high fatality rate in humans. There is limited information on localized respiratory defenses against this organism. The lab has recently shown the involvement of mast cells in early defenses against pulmonary tularemia. They are currently examining the mechanisms by which mast cells modulate innate immune defenses against this pathogen, and as a model for other Gram negative bacteria. Moreover, they are characterizing the use of defined F. tularensis mutants as live attenuated vaccine candidates against pneumonic tularemia.
Mucosal Defenses against Acinetobacter baumannii
Acinetobacter baumannii has emerged as an important nosocomial pathogen observed in injured military service personnel from the Middle East. Many multi-drug resistant strains of A. baumannii have been indentified which create additional therapeutic challenges for effective management of this infection. There is evidence to suggest that gastrointestinal colonization of A. baumannii in humans precedes the onset of other clinical conditions such as septicemia, pneumonia, and wound sepsis, with little known about the interaction of this pathogen with the gastrointestinal (GI) tract. Dr. Arulanandam’s lab has developed an oral-gastrointestinal (GI) challenge model with A. baumannii to examine the contribution of mucosal immune defenses against gastrointestinal colonization by this pathogen and the subsequent systemic manifestation of this infection.

NIH Awarded Grants icon

  Research projects funded by the National Institutes of Health (NIH), the Centers for Disease Control (CDC), the Food and Drug Administration (FDA), and the Department of Veterans Affairs (VA)

Loading
Please wait
1.
2018San Antonio Military Health System and Universities Research Forum (SURF)1R13TR002409-01
2.
2017The Contribution of MicroRNA-182 in Genital Chlamydia trachomatis Infection5R03AI117714-02
3.
2017Thioredoxin mediated Acinetobacter baumannii colonization in the GI tract5R21AI124021-02
4.
2016The Contribution of MicroRNA-182 in Genital Chlamydia trachomatis Infection1R03AI117714-01A1
5.
2016Thioredoxin mediated Acinetobacter baumannii colonization in the GI tract1R21AI124021-01
6.
2013CPAF induced CD4+ T cell mediated immunity against Chlamydia5R01AI074860-05
7.
2012Evaluation of CPAF Mediated Anti-Chlamydial Immunity in the Guinea Pig5R03AI092621-02
8.
2012CPAF induced CD4+ T cell mediated immunity against Chlamydia5R01AI074860-04
9.
2011Evaluation of CPAF Mediated Anti-Chlamydial Immunity in the Guinea Pig1R03AI092621-01
10.
2011CPAF induced CD4+ T cell mediated immunity against Chlamydia5R01AI074860-03
11.
2010CPAF induced CD4+ T cell mediated immunity against Chlamydia5R01AI074860-02
12.
2010CPAF induced CD4+ T cell mediated immunity against Chlamydia3R01AI074860-02S1
13.
2009Mapping of F. tularensis T cell epitopes in Humanized Mice5P01AI057986-05
14.
2009CPAF induced CD4+ T cell mediated immunity against Chlamydia1R01AI074860-01A2
15.
2008Mapping of F. tularensis T cell epitopes in Humanized Mice5P01AI057986-04
16.
2007Mapping of F. tularensis T cell epitopes in Humanized Mice5P01AI057986-03
17.
2006Mapping of F. tularensis T cell epitopes in Mice5P01AI057986-02
18.
2005Mapping of F. tularensis T cell epitopes in Mice1P01AI057986-01A2
19.
2004The Role of IgA in S. aureus Mediated Inflammation5R03AR048973-03
20.
2003The Role of IgA in S. aureus Mediated Inflammation5R03AR048973-02
21.
2002The Role of IgA in S. aureus Mediated Inflammation1R03AR048973-01

Publications icon

  Check NIH Public Access Policy Compliance

Loading
Please wait
1. May HC, Yu JJ, Guentzel MN, Chambers JP, Cap AP, Arulanandam BP. Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System. Front Microbiol. 2018; 9:336.
2. Trivedi NH, Yu JJ, Hung CY, Doelger RP, Navara CS, Armitige LY, Seshu J, Sinai AP, Chambers JP, Guentzel MN, Arulanandam BP. Microbial co-infection alters macrophage polarization, phagosomal escape, and microbial killing. Innate Immun. 2018 Apr; 24(3):152-162.
3. Holloway AJ, Yu J, Arulanandam BP, Hoskinson SM, Eaves-Pyles T. Cystatins 9 and C as a Novel Immunotherapy Treatment That Protects against Multidrug-Resistant New Delhi Metallo-Beta-Lactamase-1-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Mar; 62(3).
4. Nguyen JQ, Zogaj X, Adelani AA, Chu P, Yu JJ, Arulanandam BP, Klose KE. Intratracheal Inoculation of Fischer 344 Rats with Francisella tularensis. J Vis Exp. 2017 09 30; (127).
5. Keck J, Gupta R, Christenson LK, Arulanandam BP. MicroRNA mediated regulation of immunity against gram-negative bacteria. Int Rev Immunol. 2017 Sep 03; 36(5):287-299.
6. Raphael I, Webb J, Gomez-Rivera F, Chase Huizar CA, Gupta R, Arulanandam BP, Wang Y, Haskins WE, Forsthuber TG. Serum Neuroinflammatory Disease-Induced Central Nervous System Proteins Predict Clinical Onset of Experimental Autoimmune Encephalomyelitis. Front Immunol. 2017; 8:812.
7. Shao L, Melero J, Zhang N, Arulanandam B, Baseman J, Liu Q, Zhong G. The cryptic plasmid is more important for Chlamydia muridarum to colonize the mouse gastrointestinal tract than to infect the genital tract. PLoS One. 2017; 12(5):e0177691.
8. Ainsworth S, Ketter PM, Yu JJ, Grimm RC, May HC, Cap AP, Chambers JP, Guentzel MN, Arulanandam BP. Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection. Vaccine. 2017 06 08; 35(26):3387-3394.
9. Wali S, Gupta R, Yu JJ, Lanka GKK, Chambers JP, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs. Immunol Cell Biol. 2017 05; 95(5):454-460.
10. Gupta R, Arkatkar T, Keck J, Koundinya GK, Castillo K, Hobel S, Chambers JP, Yu JJ, Guentzel MN, Aigner A, Christenson LK, Arulanandam BP. Antigen specific immune response in Chlamydia muridarum genital infection is dependent on murine microRNAs-155 and -182. Oncotarget. 2016 10 04; 7(40):64726-64742.
11. Rodriguez AR, Yu JJ, Navara C, Chambers JP, Guentzel MN, Arulanandam BP. Contribution of Fc?RI-associated vesicles to mast cell-macrophage communication following Francisella tularensis infection. Innate Immun. 2016 10; 22(7):567-74.
12. Yeow TC, Wong WF, Sabet NS, Sulaiman S, Shahhosseini F, Tan GM, Movahed E, Looi CY, Shankar EM, Gupta R, Arulanandam BP, Hassan J, Abu Bakar S. Erratum: prevalence of plasmid-bearing and plasmid-free chlamydia trachomatis infection among women who visited obstetrics and gynecology clinics in Malaysia. BMC Microbiol. 2016 May 23; 16:95.
13. Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP. M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis. PLoS One. 2016; 11(4):e0153402.
14. Tan GM, Lim HJ, Yeow TC, Movahed E, Looi CY, Gupta R, Arulanandam BP, Abu Bakar S, Sabet NS, Chang LY, Wong WF. Temporal proteomic profiling of Chlamydia trachomatis-infected HeLa-229 human cervical epithelial cells. Proteomics. 2016 05; 16(9):1347-60.
15. Ketter P, Yu JJ, Cap AP, Forsthuber T, Arulanandam B. Pentraxin 3: an immune modulator of infection and useful marker for disease severity assessment in sepsis. Expert Rev Clin Immunol. 2016; 12(5):501-7.
16. Yeow TC, Wong WF, Sabet NS, Sulaiman S, Shahhosseini F, Tan GM, Movahed E, Looi CY, Shankar EM, Gupta R, Arulanandam BP, Hassan J, Abu Bakar S. Prevalence of plasmid-bearing and plasmid-free Chlamydia trachomatis infection among women who visited obstetrics and gynecology clinics in Malaysia. BMC Microbiol. 2016 Mar 18; 16:45.
17. Wali S, Gupta R, Yu JJ, Mfuh A, Gao X, Guentzel MN, Chambers JP, Abu Bakar S, Zhong G, Arulanandam BP. Guinea pig genital tract lipidome reveals in vivo and in vitro regulation of phosphatidylcholine 16:0/18:1 and contribution to Chlamydia trachomatis serovar D infectivity. Metabolomics. 2016 Apr; 12(4).
18. Lanka GK, Yu JJ, Gong S, Gupta R, Mustafa SB, Murthy AK, Zhong G, Chambers JP, Guentzel MN, Arulanandam BP. IgA modulates respiratory dysfunction as a sequela to pulmonary chlamydial infection as neonates. Pathog Dis. 2016 Apr; 74(3).
19. Arkatkar T, Gupta R, Li W, Yu JJ, Wali S, Neal Guentzel M, Chambers JP, Christenson LK, Arulanandam BP. Murine MicroRNA-214 regulates intracellular adhesion molecule (ICAM1) gene expression in genital Chlamydia muridarum infection. Immunology. 2015 Aug; 145(4):534-42.
20. Rodriguez AR, Plascencia-Villa G, Witt CM, Yu JJ, José-Yacamán M, Chambers JP, Perry G, Guentzel MN, Arulanandam BP. Chlamydia pneumoniae promotes dysfunction of pancreatic beta cells. Cell Immunol. 2015 Jun; 295(2):83-91.
21. Wali S, Gupta R, Veselenak RL, Li Y, Yu JJ, Murthy AK, Cap AP, Guentzel MN, Chambers JP, Zhong G, Rank RG, Pyles RB, Arulanandam BP. Use of a Guinea pig-specific transcriptome array for evaluation of protective immunity against genital chlamydial infection following intranasal vaccination in Guinea pigs. PLoS One. 2014; 9(12):e114261.
22. Chu P, Cunningham AL, Yu JJ, Nguyen JQ, Barker JR, Lyons CR, Wilder J, Valderas M, Sherwood RL, Arulanandam BP, Klose KE. Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates. PLoS Pathog. 2014 Oct; 10(10):e1004439.
23. Gupta R, Guentzel MN, Arulanandam BP. Reply to letter to the editor RE: "in vivo whole animal body imaging reveals colonization of Chlamydia muridarum to the lower genital tract at early stages of infection". Mol Imaging Biol. 2014 Oct; 16(5):606-7.
24. Gupta R, Wali S, Yu JJ, Chambers JP, Zhong G, Murthy AK, Bakar SA, Guentzel MN, Arulanandam BP. In vivo whole animal body imaging reveals colonization of Chlamydia muridarum to the lower genital tract at early stages of infection. Mol Imaging Biol. 2014 Oct; 16(5):635-41.
25. Cunningham AL, Dang KM, Yu JJ, Guentzel MN, Heidner HW, Klose KE, Arulanandam BP. Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112?iglB::fljB. Vaccine. 2014 Sep 08; 32(40):5234-40.
26. Ketter PM, Guentzel MN, Schaffer B, Herzig M, Wu X, Montgomery RK, Parida BK, Fedyk CG, Yu JJ, Jorgensen J, Chambers JP, Cap AP, Arulanandam BP. Severe Acinetobacter baumannii sepsis is associated with elevation of pentraxin 3. Infect Immun. 2014 Sep; 82(9):3910-8.
27. Campbell J, Huang Y, Liu Y, Schenken R, Arulanandam B, Zhong G. Bioluminescence imaging of Chlamydia muridarum ascending infection in mice. PLoS One. 2014; 9(7):e101634.
28. Gupta R, Arkatkar T, Yu JJ, Wali S, Haskins WE, Chambers JP, Murthy AK, Bakar SA, Guentzel MN, Arulanandam BP. Chlamydia muridarum infection associated host MicroRNAs in the murine genital tract and contribution to generation of host immune response. Am J Reprod Immunol. 2015 Feb; 73(2):126-40.
29. Chen J, Zhang H, Zhou Z, Yang Z, Ding Y, Zhou Z, Zhong E, Arulanandam B, Baseman J, Zhong G. Chlamydial induction of hydrosalpinx in 11 strains of mice reveals multiple host mechanisms for preventing upper genital tract pathology. PLoS One. 2014; 9(4):e95076.
30. Ketter P, Guentzel MN, Chambers JP, Jorgensen J, Murray CK, Cap AP, Yu JJ, Eppinger M, Arulanandam BP. Genome Sequences of Four Acinetobacter baumannii-A. calcoaceticus Complex Isolates from Combat-Related Infections Sustained in the Middle East. Genome Announc. 2014 Feb 06; 2(1).
31. Tang L, Yang Z, Zhang H, Zhou Z, Arulanandam B, Baseman J, Zhong G. Induction of protective immunity against Chlamydia muridarum intracervical infection in DBA/1j mice. Vaccine. 2014 Mar 10; 32(12):1407-13.
32. Li W, Murthy AK, Lanka GK, Chetty SL, Yu JJ, Chambers JP, Zhong G, Forsthuber TG, Guentzel MN, Arulanandam BP. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice. Vaccine. 2013 Nov 19; 31(48):5722-8.
33. Eaves-Pyles T, Patel J, Arigi E, Cong Y, Cao A, Garg N, Dhiman M, Pyles RB, Arulanandam B, Miller AL, Popov VL, Soong L, Carlsen ED, Coletta C, Szabo C, Almeida IC. Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis. Mol Med. 2013 Aug 28; 19:263-75.
34. Manam S, Chaganty BK, Evani SJ, Zafiratos MT, Ramasubramanian AK, Arulanandam BP, Murthy AK. Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice. PLoS One. 2013; 8(5):e64917.
35. Kamalakaran S, Chaganty BK, Gupta R, Guentzel MN, Chambers JP, Murthy AK, Arulanandam BP. Vaginal chlamydial clearance following primary or secondary infection in mice occurs independently of TNF-a. Front Cell Infect Microbiol. 2013; 3:11.
36. Trivedi NH, Guentzel MN, Rodriguez AR, Yu JJ, Forsthuber TG, Arulanandam BP. Mast cells: multitalented facilitators of protection against bacterial pathogens. Expert Rev Clin Immunol. 2013 Feb; 9(2):129-38.
37. Creecy CM, O'Neill CF, Arulanandam BP, Sylvia VL, Navara CS, Bizios R. Mesenchymal stem cell osteodifferentiation in response to alternating electric current. Tissue Eng Part A. 2013 Feb; 19(3-4):467-74.
38. Signarovitz AL, Ray HJ, Yu JJ, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Mucosal immunization with live attenuated Francisella novicida U112?iglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One. 2012; 7(10):e47639.
39. Arulanandam BP, Chetty SL, Yu JJ, Leonard S, Klose K, Seshu J, Cap A, Valdes JJ, Chambers JP. Francisella DnaK inhibits tissue-nonspecific alkaline phosphatase. J Biol Chem. 2012 Oct 26; 287(44):37185-94.
40. Hunter C, Rodriguez A, Yu JJ, Chambers J, Guentzel MN, Arulanandam B. Comparison of bone marrow-derived and mucosal mast cells in controlling intramacrophage Francisella tularensis replication. Exp Biol Med (Maywood). 2012 Jun; 237(6):617-21.
41. Rodriguez AR, Yu JJ, Guentzel MN, Navara CS, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. Mast cell TLR2 signaling is crucial for effective killing of Francisella tularensis. J Immunol. 2012 Jun 01; 188(11):5604-11.
42. Sanapala S, Yu JJ, Murthy AK, Li W, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Perforin- and granzyme-mediated cytotoxic effector functions are essential for protection against Francisella tularensis following vaccination by the defined F. tularensis subsp. novicida ?fopC vaccine strain. Infect Immun. 2012 Jun; 80(6):2177-85.
43. Maredia R, Devineni N, Lentz P, Dallo SF, Yu J, Guentzel N, Chambers J, Arulanandam B, Haskins WE, Weitao T. Vesiculation from Pseudomonas aeruginosa under SOS. ScientificWorldJournal. 2012; 2012:402919.
44. Chambers JP, Yu JJ, Jupelli M, Weintraub ST, Lopez-Ribot JL, Valdes JJ, Arulanandam BP. Alpha-1 antitrypsin is markedly decreased following pulmonary F. tularensis challenge. Front Cell Infect Microbiol. 2011; 1:20.
45. Li W, Murthy AK, Chaganty BK, Guentzel MN, Seshu J, Chambers JP, Zhong G, Arulanandam BP. Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital chlamydiamuridarum challenge. Front Immunol. 2011; 2:73.
46. Jupelli M, Murthy AK, Chaganty BK, Guentzel MN, Selby DM, Vasquez MM, Mustafa SB, Henson BM, Seidner SR, Zhong G, Arulanandam BP. Neonatal chlamydial pneumonia induces altered respiratory structure and function lasting into adult life. Lab Invest. 2011 Oct; 91(10):1530-9.
47. Thathiah P, Sanapala S, Rodriguez AR, Yu JJ, Murthy AK, Guentzel MN, Forsthuber TG, Chambers JP, Arulanandam BP. Non-FceR bearing mast cells secrete sufficient interleukin-4 to control Francisella tularensis replication within macrophages. Cytokine. 2011 Aug; 55(2):211-20.
48. Murthy AK, Li W, Chaganty BK, Kamalakaran S, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, Arulanandam BP. Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection. Infect Immun. 2011 Jul; 79(7):2928-35.
49. King MD, Guentzel MN, Arulanandam BP, Bodour AA, Brahmakshatriya V, Lupiani B, Chambers JP. Effects of bacterial microflora of the lower digestive tract of free-range waterfowl on influenza virus activation. Appl Environ Microbiol. 2011 Jun; 77(12):4119-25.
50. Chu P, Rodriguez AR, Arulanandam BP, Klose KE. Tryptophan prototrophy contributes to Francisella tularensis evasion of gamma interferon-mediated host defense. Infect Immun. 2011 Jun; 79(6):2356-61.
51. Nallaparaju KC, Yu JJ, Rodriguez SA, Zogaj X, Manam S, Guentzel MN, Seshu J, Murthy AK, Chambers JP, Klose KE, Arulanandam BP. Evasion of IFN-? signaling by Francisella novicida is dependent upon Francisella outer membrane protein C. PLoS One. 2011 Mar 31; 6(3):e18201.
52. Murthy AK, Chaganty BK, Troutman T, Guentzel MN, Yu JJ, Ali SK, Lauriano CM, Chambers JP, Klose KE, Arulanandam BP. Mannose-containing oligosaccharides of non-specific human secretory immunoglobulin A mediate inhibition of Vibrio cholerae biofilm formation. PLoS One. 2011 Feb 09; 6(2):e16847.
53. Murthy AK, Li W, Guentzel MN, Zhong G, Arulanandam BP. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. Vaccine. 2011 Mar 21; 29(14):2519-22.
54. Ji N, Rao N, Guentzel NM, Arulanandam BP, Forsthuber TG. Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin. J Immunol. 2011 Mar 01; 186(5):2750-6.
55. Evani SJ, Murthy AK, Mareedu N, Montgomery RK, Arulanandam BP, Ramasubramanian AK. Hydrodynamic regulation of monocyte inflammatory response to an intracellular pathogen. PLoS One. 2011 Jan 07; 6(1):e14492.
56. Murphey C, Chang S, Zhang X, Arulanandam B, Forsthuber TG. Induction of polyclonal CD8+ T cell activation and effector function by Pertussis toxin. Cell Immunol. 2011; 267(1):50-5.
57. Rodriguez AR, Yu JJ, Murthy AK, Guentzel MN, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. Mast cell/IL-4 control of Francisella tularensis replication and host cell death is associated with increased ATP production and phagosomal acidification. Mucosal Immunol. 2011 Mar; 4(2):217-26.
58. Li W, Murthy AK, Guentzel MN, Chambers JP, Forsthuber TG, Seshu J, Zhong G, Arulanandam BP. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. Infect Immun. 2010 Sep; 78(9):3942-9.
59. Jupelli M, Selby DM, Guentzel MN, Chambers JP, Forsthuber TG, Zhong G, Murthy AK, Arulanandam BP. The contribution of interleukin-12/interferon-gamma axis in protection against neonatal pulmonary Chlamydia muridarum challenge. J Interferon Cytokine Res. 2010 Jun; 30(6):407-15.
60. Ray HJ, Chu P, Wu TH, Lyons CR, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The Fischer 344 rat reflects human susceptibility to francisella pulmonary challenge and provides a new platform for virulence and protection studies. PLoS One. 2010 Apr 01; 5(4):e9952.
61. Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010 Mar 08; 28(11):2323-9.
62. Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clin Vaccine Immunol. 2010 Feb; 17(2):215-22.
63. Barker JR, Chong A, Wehrly TD, Yu JJ, Rodriguez SA, Liu J, Celli J, Arulanandam BP, Klose KE. The Francisella tularensis pathogenicity island encodes a secretion system that is required for phagosome escape and virulence. Mol Microbiol. 2009 Dec; 74(6):1459-70.
64. Murthy AK, Guentzel MN, Zhong G, Arulanandam BP. Chlamydial protease-like activity factor--insights into immunity and vaccine development. J Reprod Immunol. 2009 Dec; 83(1-2):179-84.
65. Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009 Sep 18; 27(41):5554-61.
66. King MD, Guentzel MN, Arulanandam BP, Lupiani B, Chambers JP. Proteolytic bacteria in the lower digestive tract of poultry may affect avian influenza virus pathogenicity. Poult Sci. 2009 Jul; 88(7):1388-93.
67. Zhang X, Gao L, Lei L, Zhong Y, Dube P, Berton MT, Arulanandam B, Zhang J, Zhong G. A MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum. J Immunol. 2009 Jul 15; 183(2):1291-300.
68. Murthy AK, Chaganty BK, Li W, Guentzel MN, Chambers JP, Seshu J, Zhong G, Arulanandam BP. A limited role for antibody in protective immunity induced by rCPAF and CpG vaccination against primary genital Chlamydia muridarum challenge. FEMS Immunol Med Microbiol. 2009 Mar; 55(2):271-9.
69. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
70. Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9313-8.
71. Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
72. Jupelli M, Guentzel MN, Meier PA, Zhong G, Murthy AK, Arulanandam BP. Endogenous IFN-gamma production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol. 2008 Mar 15; 180(6):4148-55.
73. Li W, Murthy AK, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, Arulanandam BP. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol. 2008 Mar 01; 180(5):3375-82.
74. Rodriguez SA, Yu JJ, Davis G, Arulanandam BP, Klose KE. Targeted inactivation of francisella tularensis genes by group II introns. Appl Environ Microbiol. 2008 May; 74(9):2619-26.
75. Chambers JP, Arulanandam BP, Matta LL, Weis A, Valdes JJ. Biosensor recognition elements. Curr Issues Mol Biol. 2008; 10(1-2):1-12.
76. Yu JJ, Raulie EK, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge. Eur J Clin Microbiol Infect Dis. 2008 Apr; 27(4):323-5.
77. Li W, Guentzel MN, Seshu J, Zhong G, Murthy AK, Arulanandam BP. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin Vaccine Immunol. 2007 Dec; 14(12):1537-44.
78. Daum LT, Canas LC, Arulanandam BP, Niemeyer D, Valdes JJ, Chambers JP. Real-time RT-PCR assays for type and subtype detection of influenza A and B viruses. Influenza Other Respir Viruses. 2007 Jul; 1(4):167-75.
79. Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine. 2007 May 10; 25(19):3773-80.
80. Rodriguez AR, Arulanandam BP, Hodara VL, McClure HM, Cobb EK, Salas MT, White R, Murthy KK. Influence of interleukin-15 on CD8+ natural killer cells in human immunodeficiency virus type 1-infected chimpanzees. J Gen Virol. 2007 Feb; 88(Pt 2):641-51.
81. Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2007 Feb; 75(2):666-76.
82. Murphey C, Murthy AK, Meier PA, Neal Guentzel M, Zhong G, Arulanandam BP. The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells. Cell Immunol. 2006 Aug; 242(2):110-7.
83. Murthy AK, Cong Y, Murphey C, Guentzel MN, Forsthuber TG, Zhong G, Arulanandam BP. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun. 2006 Dec; 74(12):6722-9.
84. Murthy AK, Dubose CN, Banas JA, Coalson JJ, Arulanandam BP. Contribution of polymeric immunoglobulin receptor to regulation of intestinal inflammation in dextran sulfate sodium-induced colitis. J Gastroenterol Hepatol. 2006 Sep; 21(9):1372-80.
85. Chen C, Chen D, Sharma J, Cheng W, Zhong Y, Liu K, Jensen J, Shain R, Arulanandam B, Zhong G. The hypothetical protein CT813 is localized in the Chlamydia trachomatis inclusion membrane and is immunogenic in women urogenitally infected with C. trachomatis. Infect Immun. 2006 Aug; 74(8):4826-40.
86. Daum LT, Canas LC, Klimov AI, Shaw MW, Gibbons RV, Shrestha SK, Myint KS, Acharya RP, Rimal N, Reese F, Niemeyer DM, Arulanandam BP, Chambers JP. Molecular analysis of isolates from influenza B outbreaks in the U.S. and Nepal, 2005. Arch Virol. 2006 Sep; 151(9):1863-74.
87. Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun. 2006 Apr; 74(4):2063-71.
88. Dong F, Zhong Y, Arulanandam B, Zhong G. Production of a proteolytically active protein, chlamydial protease/proteasome-like activity factor, by five different Chlamydia species. Infect Immun. 2005 Mar; 73(3):1868-72.
89. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother. 2004 Dec; 48(12):4513-9.
90. Murthy AK, Sharma J, Coalson JJ, Zhong G, Arulanandam BP. Chlamydia trachomatis pulmonary infection induces greater inflammatory pathology in immunoglobulin A deficient mice. Cell Immunol. 2004 Jul; 230(1):56-64.
91. Lauriano CM, Barker JR, Yoon SS, Nano FE, Arulanandam BP, Hassett DJ, Klose KE. MglA regulates transcription of virulence factors necessary for Francisella tularensis intraamoebae and intramacrophage survival. Proc Natl Acad Sci U S A. 2004 Mar 23; 101(12):4246-9.
92. Lauriano CM, Barker JR, Nano FE, Arulanandam BP, Klose KE. Allelic exchange in Francisella tularensis using PCR products. FEMS Microbiol Lett. 2003 Dec 12; 229(2):195-202.
93. Nagatomi J, Arulanandam BP, Metzger DW, Meunier A, Bizios R. Cyclic pressure affects osteoblast functions pertinent to osteogenesis. Ann Biomed Eng. 2003 Sep; 31(8):917-23.
94. Huber VC, Arulanandam BP, Arnaboldi PM, Elmore MK, Sheehan CE, Kallakury BV, Metzger DW. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol. 2003 Jun; 3(6):801-9.
95. Nagatomi J, Arulanandam BP, Metzger DW, Meunier A, Bizios R. Effects of cyclic pressure on bone marrow cell cultures. J Biomech Eng. 2002 Jun; 124(3):308-14.
96. Supronowicz PR, Ajayan PM, Ullmann KR, Arulanandam BP, Metzger DW, Bizios R. Novel current-conducting composite substrates for exposing osteoblasts to alternating current stimulation. J Biomed Mater Res. 2002 Mar 05; 59(3):499-506.
97. Nagatomi J, Arulanandam BP, Metzger DW, Meunier A, Bizios R. Frequency- and duration-dependent effects of cyclic pressure on select bone cell functions. Tissue Eng. 2001 Dec; 7(6):717-28.
98. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun. 2001 Nov; 69(11):6718-24.
99. Refici ML, Metzger DW, Arulanandam BP, Lennartz MR, Loegering DJ. Fcgamma-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-alpha levels. Am J Physiol Regul Integr Comp Physiol. 2001 Apr; 280(4):R1037-44.
100. Buchanan RM, Briles DE, Arulanandam BP, Westerink MA, Raeder RH, Metzger DW. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine. 2001 Feb 28; 19(15-16):2020-8.
101. Arulanandam BP, Raeder RH, Nedrud JG, Bucher DJ, Le J, Metzger DW. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J Immunol. 2001 Jan 01; 166(1):226-31.
102. Arulanandam BP, Mittler JN, Lee WT, O'Toole M, Metzger DW. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol. 2000 Apr 01; 164(7):3698-704.
103. Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999 Oct; 180(4):940-9.
104. Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 1999 Jan 21; 17(3):252-60.
105. Arulanandam BP, Van Cleave VH, Metzger DW. IL-12 is a potent neonatal vaccine adjuvant. Eur J Immunol. 1999 01; 29(1):256-64.
106. Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol. 1998 Nov 15; 161(10):5525-33.
107. Lyte M, Erickson AK, Arulanandam BP, Frank CD, Crawford MA, Francis DH. Norepinephrine-induced expression of the K99 pilus adhesin of enterotoxigenic Escherichia coli. Biochem Biophys Res Commun. 1997 Mar 27; 232(3):682-6.
108. Lyte M, Arulanandam B, Nguyen K, Frank C, Erickson A, Francis D. Norepinephrine induced growth and expression of virulence associated factors in enterotoxigenic and enterohemorrhagic strains of Escherichia coli. Adv Exp Med Biol. 1997; 412:331-9.
109. Lyte M, Arulanandam BP, Frank CD. Production of Shiga-like toxins by Escherichia coli O157:H7 can be influenced by the neuroendocrine hormone norepinephrine. J Lab Clin Med. 1996 Oct; 128(4):392-8.

Research Resources icon

Funding Opportunities icon

Browse active NIH & NSF funding opportunities, requests for applications (RFAs), and program announcements (PAs)

Publications Timeline

Top MeSH Keywords

Tree Map of Keyword Semantic Groups (Categories)

Left-click a node to move down the tree, right-click the graph to move back up the tree

Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile:
 
Keyword
Last Name
Institution
 
See all (13) people See all (60) people Search for (37) people
Feedback

RTRN Collaboration and Professional Networking Feedback